



(43) International Publication Date
1 November 2012 (01.11.2012)

(10) International Publication Number
WO 2012/148494 A3

- (51) **International Patent Classification:**
A01N 43/02 (2006.01) *A61K 31/335* (2006.01)
- (21) **International Application Number:**
PCT/US2012/000217
- (22) **International Filing Date:**
23 April 2012 (23.04.2012)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
13/066,793 25 April 2011 (25.04.2011) US
- (71) **Applicant (for all designated States except US):** SAVVI-PHARM INC [US/US]; 99 Wall Street, 23rd Floor, New York, NY 10005 (US).
- (72) **Inventor; and**
- (75) **Inventor/Applicant (for US only):** KARMALI, Rashida, A.; 99 Wall Street, 23rd Floor, New York, NY 10005 (US).
- (74) **Agent:** KARMALI, Rashida, A.; 99 Wall Street, 23rd Floor, New York, NY 10005 (US).
- (81) **Designated States (unless otherwise indicated, for every kind of national protection available):** AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

- (84) **Designated States (unless otherwise indicated, for every kind of regional protection available):** ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

- (88) **Date of publication of the international search report:**
17 April 2014

(54) **Title:** PHARMACEUTICAL COMPOSITIONS CONTAINING PACLITAXEL OROTATE

(57) **Abstract:** This invention is related to orotic acid compounds of taxane cytotoxic agents and in particular to the conversion of the taxanes to their orotate esters. More particularly the pharmaceutical compositions of paclitaxel orotate and docetaxel orotate provide a strategy to minimize body weight loss during primary chemotherapy and improve patient outcomes and quality of life.



WO 2012/148494 A3

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 12/00217

A. CLASSIFICATION OF SUBJECT MATTER

IPC(8) - A01N 43/02; A61K 31/335 (2012.01)

USPC - 514/449

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

USPC: 514/449

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

USPC: 514/449; 549/510 (see search terms below)

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

DialogClassic: (Keywords: Paclitaxel, orotate, oral, orotic acid, derivative, analogue)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 7,601,834 B2 (Karmali) 13 Oct. 2009 (13.10.2009) col 6, ln 32-46	1-2
P/A	US 8,034,823 B2 (Karmali) 11 Oct. 2011 (11.10.2011) entire document	1-2
A	US 7,470,672 B2 (Karmali) 30 Dec. 2008 (30.12.2008) entire document	1-2
A	US 2009/0131344 A1 (Karmali) 21 May 2009 (21.05.2009) entire document	1-2
A	US 2008/0025949 A1 (Karmali) 31 Jan. 2008 (31.01.2008) entire document	1-2
A	US 2007/0179145 A1 (Karmali) 2 Aug. 2007 (02.08.2007) entire document	1-2
A	US 2006/0189640 A1 (Karmali) 24 Aug. 2006 (24.08.2006) entire document	1-2

☐ Further documents are listed in the continuation of Box C.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

25 June 2012 (25.06.2012)

Date of mailing of the international search report

07 AUG 2012

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents
P.O. Box 1450, Alexandria, Virginia 22313-1450

Facsimile No. 571-273-3201

Authorized officer:

Lee W. Young

PCT Helpdesk: 571-272-4300
PCT OSP: 571-272-7774